Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-27
    E.g., 2018-06-27

Articles

19281 items
12:00 AM, Jun 21, 1993  |  BioCentury | Politics, Policy & Law

BST, capital gains tangled in budget bill

BST, capital gains tangled in budget bill WASHINGTON -- A proposed moratorium on the use of bovine somatotropin has been tacked onto a package of spending cuts that probably will be considered by the Senate...
12:00 AM, Jun 21, 1993  |  BioCentury | Regulation

Snowballing

The brutal treatment Vestar Inc.'s DaunoXome received at the hands of an FDA advisory panel last week should provide a stiff poke in the ribs to any biotech executive who isn't building an end-game strategy...
12:00 AM, Jun 14, 1993  |  BioCentury | Regulation

Surrogate marker guidelines at hand

Surrogate marker guidelines at hand Coincident to the pending decision by Immunization Products Ltd. on whether to seek accelerated FDA approval of its HIV therapeutic vaccine, the agency is close to completing a year-long review...
12:00 AM, Jun 14, 1993  |  BioCentury | Finance

Worst of both worlds

Worst of both worlds Immune Response Corp. shares suffered a 40 percent shellacking last week, which we suppose could be attributed to inconclusive data from the Phase II/III trial of its HIV therapeutic vaccine. Or,...
12:00 AM, Jun 14, 1993  |  BioCentury | Strategy

Two birds, one stone kind of deal

Two birds, one stone kind of deal Neurex Corp. 's second partnering deal should add some appeal to its long-postponed initial public offering, once the financing window reopens. Under the terms of...
12:00 AM, Jun 14, 1993  |  BioCentury | Strategy

Agouron, Syntex look ahead to the clinic

Agouron, Syntex look ahead to the clinic A new collaboration between Agouron Pharmaceuticals Inc. (AGPH) and Syntex Corp. should provide products ready for clinical trials in both arthritis and cancer within...
12:00 AM, Jun 07, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Chiron Corp. (CHIR) BETASERON APPROVAL: David Stone of Cowen & Co. reiterated his "buy" on Chiron Corp., on the expectation that CHIR and partner Berlex will receive FDA approval to market Betaseron in the near...
12:00 AM, Jun 07, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

T Cell Sciences Robert Peterson of Hanifen, Imhoff upgraded T Cell Sciences to "buy" from "hold," with a 12-month price target of $11-$17 based solely on revenues from its TRAx CD4 test and other diagnostic...
12:00 AM, Jun 07, 1993  |  BioCentury | Product Development

CNTO says housecleaning is done

Centocor Inc. hopes that it has dropped the last shoe with its withdrawal of product license applications for Myoscint and Fibriscint, culminating a wrenching series of surprises and course corrections at the company....
12:00 AM, Jun 07, 1993  |  BioCentury | Product Development

Univax reaches first product milestone

Univax Biologics Inc. (UNVX) filed its first product license application with the FDA, to market WinRho SD for treatment of idiopathic thrombocytopenic purpura (ITP), a blood disorder characterized by...

Pages